Apr 1 • 1 min read

PRO: Rapid Reactions To ATAI’s 2021 Year-End Financial Results

atai Life Sciences (ATAI), the largest pureplay clinical-stage psychedelic company in our index, just reported financial results for the fourth quarter and full-year ended December 31, 2021. The announcement falls on the heels of Compass Pathways (CMPS), Field Trip Health (FTRP), and Mind Medicine (MNMD) all announcing their year-end results, marking a suitable time for…

You must have PRO to access this content.

Become a Pro

Do you want to know more about these companies?

ATAI atai Life Sciences

CMPS COMPASS Pathways

MNMD MindMed

PRO: Rapid Reactions To ATAI’s 2021 Year-End Financial Results

Do you want to know more about these companies?

Track the entire psychedelic market using the only index that covers the entire psychedelics marketplace.

Nucleus Ecosystem

PRO: Rapid Reactions To ATAI’s 2021 Year-End Financial Results

Do you want to know more about these companies?

Track the entire psychedelic market using the only index that covers the entire psychedelics marketplace.

Related Articles

MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)

MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)

MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy